Skip to content

Drug - Food interaction of Oseltamivir(Tamiflu) in oral absorption

Drug - Food interaction of Oseltamivir(Tamiflu) in oral absorption - Drug - Food interaction of Oseltamivir(Tamiflu) in oral absorption

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003702
Enrollment
6
Registered
2010-08-01
Start date
2010-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

The Tamiflu capsule is taken with water. The Tamiflu capsule is taken with milk.

Sponsors

Takuo Ogihara
Lead Sponsor
Medical corporation LTA Sumida Hospital
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: the investigators must ensure that all subjects being considered to meet the following inclusion criteria: 1) healthy male who is capable to understand and sign the informed consent. 2) male between 20 and <45 years of age on the day of signing informed consent 3)Body Mass Indes(BMI) between 17.6 and 26.4 kg/m2 inclusive 4)good health as determined by physical examination and laboratory tests etc.

Exclusion criteria

Exclusion criteria: the investigators must ensure that all subjects being considered to meet the following exclusion criteria or conditions: 1)history of allergy to Oseltamivir 2)difficult to take milk because of lactose intolerance etc. 3)disease thought to be decreased metabolic function of liver(acute hepatitis,chronic hepatitis,hepatic cirrhosis,liver carcinoma,jaundice) 4)decreased metabolic function of kidney 5)electrocardiogram (ECG) showing a QTc>460 msec 6)who take any drugs or supplement including St.John's wort within a week prior to test drug administration 7)fruit juice including grapefruit, orange or apple within 7 days prior to test drug administration 8)recent (past 3 months) participation in other clinical trial for investigational agent,the investigator determines this trial participation inadequate 9)donation of 400mL or more of blood within 3 months prior to participation, donation of 200mL or more of blood within 1 month prior to participation 10)any positive results of HBs-AG,HCV-AB,HIV AB,HIV AG,TPHA. 11)history of allergy to any medicines and foods 12)history of drug or alcohol abusement 13) the investigator determines inadequate

Design outcomes

Primary

MeasureTime frame
PK profiles of Oseltamivir and it's metabolite Ro64-0802 in plasma and urine

Countries

Japan

Contacts

Public ContactAkihiro Inano

Neues Corporation Clinical research support

inano.akihiro@neues.co.jp092-283-7100

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026